Actively Recruiting
Evaluating Safety and Effects of Intravesical Sacituzumab Tirumotecan in Intermediate-risk Non-Muscle Invasive Bladder Cancer Participants
Led by Merck Sharp & Dohme LLC · Updated on 2026-10-15
32
Participants Needed
13
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety and tolerability of Sacituzumab Tirumotecan when given directly into the bladder in people with intermediate-risk non-muscle invasive bladder cancer NMIBC. This phase 12 open-label study aims to find the highest dose participants can take without significant problems and to select a dose for future studies to evaluate how well the drug works. Participants will receive intravesical Sacituzumab Tirumotecan once a week for six weeks. The study may also include the use of rescue medications and supportive care measures to manage side effects. The study is designed as a single group where all participants receive the experimental treatment. During the study, participants will be closely monitored for dose-limiting toxicities and adverse events, with safety assessments over approximately 6 to 10 weeks. Researchers will also measure drug levels in the blood and evaluate treatment response up to 24 months. The total participation duration can be up to two years for some outcome measures.
CONDITIONS
Brief Title
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Research Team
T
Toll Free Number
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here